Jin Rong Jie·2026-01-13 03:54Group 1 - The core viewpoint of the articles highlights the significant rise in the Hong Kong stock market, particularly in the pharmaceutical and media sectors, with specific stocks like the Southern Biotech ETF and WuXi AppTec showing notable gains [1] - The application of artificial intelligence (AI) in the pharmaceutical industry is transitioning from experimental trials to a focus on core business value creation, with a consensus that by 2026, competitive differentiation will rely on systematic restructuring of personnel, processes, and data infrastructure [1] - AI is expected to play a crucial role in enhancing drug development and commercialization, with industry-specific AI agents becoming key to coordinating business activities and providing real-time insights [1] Group 2 - The small nucleic acid drug sector is expanding into kidney diseases, which is anticipated to become a new value hotspot by 2026, driven by key clinical data and strong concept validation from international giants [2] - Domestic innovative companies are rapidly following suit, creating a differentiated competitive landscape, with leading pharmaceutical firms advancing clinical pipelines targeting C5 and developing novel siRNA products [2] - The relatively unsaturated competition in the kidney sector and the patient compliance advantages of long-acting small nucleic acid drugs position it as a visible area for value growth [2]